CJC-1295 acts as a long-acting analog of growth hormone-releasing hormone (GHRH), stimulating the GHRH receptor on pituitary somatotrophs, which activates the cAMP/PKA signaling pathway leading to increased secretion of growth hormone (GH). This, in turn, enhances insulin-like growth factor I (IGF-I) production via the GH receptor, promoting anabolic processes such as protein synthesis, tissue growth, and regeneration. While the precise mechanisms underlying its prolonged effects are not fully understood, it is known to sustain elevated GH and IGF-I levels, influencing metabolic and regenerative pathways.